(2025) [40], were conducted in adults with obesity (typically BMI 30 kg/m 2 ), most of whom had comorbid type 2 diabetes and consistently excluded individuals with active, severe, or unstable psychiatric disorders
However, because retatrutide remains investigational, its benefits must be interpreted alongside its evolving safety profile, dose-related side effects, and the need for ongoing clinical monitoring
(Ed.), Cummings Otolaryngology: Head & Neck Surgery (5th ed.)
T3, the active thyroid hormone, decreases as the body attempts to conserve energy
Lin Y, Lin B, Chen Y, Zheng Z, Fu Q, Lin W, et al
Editors note: This report has been updated to reflect findings from the TRIUMPH-1 clinical trial released on May 21, 2026 by Eli Lilly and Company.